The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome

Author： McLaughlin John   Houghton Lesley A  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.5, Iss.2, 2006-03, pp. : 313-327

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Review of tegaserod in the treatment of irritable bowel syndrome

By Patel Sonal   Berrada Driss   Lembo Anthony  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 11, 2004-11 ,pp. : 2369-2379

Informa Healthcare

Access to resources Recommend Favorite

Safety Profile of Tegaserod, a 5-HT 4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome

By Hasler W.L.   Schoenfeld P.  

Drug Safety, Vol. 27, Iss. 9, 2004-01 ,pp. : 619-631

Adis International

Access to resources Recommend Favorite

Tegaserod effective in irritable bowel syndrome

By  

Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review

By  

Current Drug Targets, Vol. 19, Iss. 15, 2018-12 ,pp. : 1774-1781

Bentham Science Publishers

Access to resources Recommend Favorite

Tegaserod: a new 5-HT4 agonist in the treatment of irritable bowel syndrome

By Tack Jan   Corsetti Maura  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 8, 2002-08 ,pp. : 1211-1218

Informa Healthcare

Access to resources Recommend Favorite